Global giant out to ruin deal: Ranbaxy
HIT hard by mounting scrutiny and falling stocks, Ranbaxy CEO and MD Malvinder Singh said a big global pharma company was trying to scuttle the deal with Daiichi Sankyo. "This is part of a larger game of a global innovater company to block low-cost generic drugs,'' he said.